Eton Pharmaceuticals Enters Into License Agreement for Two Branded Hospital Product Candidates
Eton Pharmaceuticals, Inc. recently announced that it has entered into an exclusive licensing and supply agreement with Sintetica SA, a Swiss-based pharmaceutical company, to obtain US marketing rights to two injectable product candidates. With the addition of these product candidates, Eton now has three product candidates submitted with the FDA and expects to submit two additional NDAs by the third quarter of 2019.
The licensed product candidates provide Eton with two high-volume, near-term product launch opportunities. The NDA for ET-202 was submitted to the FDA in December 2018 and Eton expects to receive a fourth quarter 2019 Prescription Drug User Fee Act (PDUFA) date. The NDA for ET-203 is expected to be submitted by the third quarter of 2019.
Both products are innovative ready-to-use formulas of existing injectable products that Eton believes to be two of the highest volume compounded products in the hospital setting. The existing FDA-approved products are only available in concentrated versions that must be diluted prior to administration to patients. Hospitals currently purchase non-FDA approved ready-to-use products from compounding facilities, or manually dilute the products in-house. The newly licensed product candidates have been developed in ready-to-use strengths that can be immediately administered in patients, eliminating the need for additional dilution steps. Eton believes that if approved, ET-202 and ET-203 will offer significant benefits to hospitals over the current compounded products, including:
-Elimination of compounding errors due to incorrect drug or concentration
-Significantly higher level of sterility assurance
-More consistent supply
-FDA reviewed for safety and efficacy
-Time and cost savings compared to in-house compounding
-Elimination of regulatory risk associated with in-house compounding
Eton estimates the combined addressable market for the products to be in excess of 10 million units annually. The company believes that, if approved, the compelling potential benefits of these ready-to-use products would enable it to take a significant share of the market.
“We are very excited to partner with Sintetica and add an additional 2019 product launch opportunity to our pipeline,” said Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals. “These potentially high volume hospital product candidates are an ideal strategic fit with Eton’s ongoing mission to bring safe, approved pharmaceutical products to markets that are currently reliant on compounded and unapproved products. We plan to immediately begin launch preparation activities in order to facilitate successful commercialization of these important products if approved.”
“Sintetica, a recognized leader in innovative formulations, is very pleased to have entered into a partnership with Eton Pharmaceuticals. The combination of high quality manufacturing and dynamic product development at Sintetica, and Eton’s energy and experience in the American market make this great for all stakeholders,” said Pasquale Mitidieri, Director of the Global Division of Sintetica S.A.
Under terms of the agreement, Sintetica will supply product to Eton at its direct costs and profit from Eton’s commercial sales will be shared equally by both parties. Eton will pay Sintetica $3 million upon execution of the agreements and will be obligated to pay an additional $750,000 upon approval of each product.
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative products utilizing the FDA’s 505(b)(2) regulatory pathway. Eton is primarily focused on liquid dosage forms including injectables, oral liquids, and ophthalmics. Eton has a diversified pipeline of high-value product candidates in various stages of development and therapeutic areas, including multiple product candidates currently pending regulatory approval with the FDA.
Total Page Views: 404